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Abstract Through years of evolutionary selection pres-
sures, organisms have developed potent toxins that coin-
cidentally have marked antineoplastic activity. These
natural products have been vital for the development of
multiagent treatment regimens currently employed in
cancer chemotherapy, and are used in the treatment of a
variety of malignancies. Therefore, this review catalogs
recent advances in natural product-based drug discovery
via the examination of mechanisms of action and available
clinical data to highlight the utility of these novel com-
pounds in the burgeoning age of precision medicine. The
review also highlights the recent development of antibody-
drug conjugates and other immunotoxins, which are cap-
able of delivering highly cytotoxic agents previously
deemed too toxic to elicit therapeutic benefit preferentially
to neoplastic cells. Finally, the review examines natural
products not currently used in the clinic that have novel
mechanisms of action, and may serve to supplement cur-
rent chemotherapeutic protocols.
Key Points
Natural products have potentiated many novel drug
classes employed in cancer chemotherapy, including
mechanistic target of rapamycin inhibitors, protein
synthesis inhibitors, nucleic acid-directed agents,
and microtubule-directed agents
Recent advances in immunotherapy have enabled
highly cytotoxic natural products to be targeted
towards specific tissues
There are still many natural products with
mechanisms not currently seen in the clinical setting
that could be very beneficial to the field of oncology
1 Introduction
The diversity of natural products currently used in the
clinical setting to treat solid tumors, as well as dissemi-
nated cancers is truly extensive. Under the pressure of
natural selection, various species produce cytotoxic sec-
ondary metabolites to combat potential predators, prey, or
competition in the so-called ‘‘arms race’’ of evolution.
Remarkably, some of these natural toxins appear to exhibit
potent antineoplastic activity, and after years of research,
have found their way from the ocean or soil to the highly
heterogeneous environment of clinical oncology. The ori-
gins of cancer chemotherapy can be traced to human-made
compounds, as Goodman, Gilman, and colleagues at Yale
University began investigating the potential of nitrogen
mustards in 1942 [1], which was shortly followed by
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Sidney Farber’s use of the antifolate aminopterin to induce
remissions among children with leukemia in 1947 [2, 3].
However, the institution of natural products and semisyn-
thetic derivatives of these compounds in the latter part of
the 20th century potentiated the idea of concomitant
chemotherapy; using a variety of antineoplastic agents with
different mechanisms of action to significantly perturb
neoplastic development, and in some cases, produce long-
term remissions.
Owing to recent advances in molecular biology, inves-
tigators have begun unraveling essential oncogenic path-
ways in carcinogenesis, potentiating an era of
chemotherapy in which it is possible to theorize cancer-
specific targets. This has launched the introduction of
precision medicine in cancer chemotherapy in which
clinicians now have the capability of selecting optimal
therapies based on the genetic and phenotypic profile of the
patient’s malignancy in addition to traditional broad-
spanning cytotoxic antineoplastic intervention. Despite
these commendable advances in targeted therapy, natural
products and their derivatives are still extensively relied
upon against malignancies where finding cancer-specific
targets has been less successful, and are often used in
combination with these targeted approaches to generate
more thorough treatment protocols. Further, novel natural
product derivatives have shown notably efficacy against
previously unresponsive malignancies at the clinical level,
suggesting that natural product-based drug discovery still
has considerable utility in the burgeoning era of personal-
ized chemotherapy. Finally, natural products have the
potential to improve novel immunotherapeutic strategies
by conjugating monoclonal antibodies (mABs) or cytoki-
nes to highly cytotoxic compounds that have too low of a
therapeutic index without an appropriate guidance
mechanism.
This review catalogs recent advances in natural product
drug discovery that have potentiated promising activity
against aggressive malignancies, and have enabled a more
precise delivery of highly cytotoxic, natural product-based
agents to reduce unintended side effects. Specifically, this
review covers the commendable advances in the develop-
ment of microtubule-directed agents (eribulin and epothi-
lones), mechanistic target of rapamycin (mTOR) inhibitors
(everolimus and temsirolimus), protein synthesis inhibitors
(omacetaxine mepesuccinate), nucleic acid-directed agents
(trabectedin), engineered cytokine proteins (denileukin
diftitox), and antibody-drug conjugates (ADCs; brentux-
imab vedotin, trastuzumab emtansine, calicheamicin con-
jugated monoclonal antibodies, and exotoxin conjugates).
In addition, the review will highlight several novel natural
products that act by mechanisms not currently seen in the
clinic (cytochalasins and withanolides) to address their
potential utility in cancer chemotherapy. Although this
review provides an extensive coverage of novel natural
product-based antineoplastic agents, additional agents have
seen recent success in the clinical setting, and the reader is
referred to the following reviews for further information
[4–6]. In addition, the diversity of natural product-based
antineoplastic agents and their derivatives currently
approved by the US Food and Drug Administration (FDA)
are highlighted in Table 1. They serve as a reminder of
how important nature has been in the treatment of many, if
not most types of malignancy.
2 Microtubule-Disrupting Eribulin
Eribulin is a fully synthetic, macrocyclic ketone analog of
the marine sponge natural product halichondrin B (Fig. 1),
a potent antimitotic initially isolated in 1986 from Hali-
chondria okadai [7]. Although halicondrin B was desig-
nated for preclinical development after it was found to be
highly cytotoxic against murine leukemia cells, difficulty
in collecting sufficient material for developmental studies
slowed its progress, and interest began to fade. However,
the discovery that halocondrin B activity resides in the
macrocyclic lactone C-1 to C-38 moiety [8] paved the way
for development of a simplified synthetic analog, culmi-
nating in the design of eribulin.
As with vinca alkaloids, eribulin exerts its cytotoxic
effects by interfering with microtubule dynamics, and
inhibiting polymerization [9, 10]. In addition, eribulin
also works through an end-poisoning mechanism, result-
ing in the inhibition of microtubule growth, and even
sequesters tubulin into nonfunctional aggregates, pro-
moting G2/M phase arrest and apoptosis [11]. However,
the two drug classes contrast in that eribulin does not bind
the sides of tubulin polymers, and therefore does not
markedly potentiate depolymerization [12, 13]. It does
suppress spindle microtubule tension by interfering with
centromere dynamics, as seen with some vinca alkaloids
(particularly vinorelbine and vinflunine), but does so by
inhibiting relaxation rates and the time spent stretching
and relaxing, without the corresponding suppressive
effects on stretching rates observed with the other agents
[14]. Further, eribulin inhibits tubulin polymerization by
binding the interdimer interface or the b-tubulin subunit
alone contrary to other microtubule-directed agents,
including epothilones and taxanes [12]. Interestingly,
eribulin demonstrates significant activity against bIII-
tubulin, an isotype that is overexpressed in cells resistant
to microtubule inhibitors [15, 16], indicative of its unique
clinical utility.
In regard to its clinical pharmacologic profile, eribulin
demonstrates linear pharmacokinetics with rapid systemic
distribution, but has a t1/2 of 40 h and around 49–65 %
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Table 1 US Food and Drug Administration (FDA) approved uses of natural products in cancer chemotherapy






Inhibits protein synthesis and is
independent of direct Bcr-Abl binding
Chronic- or accelerated-phase CML with






Topo II inhibitor, intercalating agent Remission induction in adult AML or in
both children and adults for ALL






Topo II inhibitor, intercalating agent ALL, AML, Wilms tumor,
neuroblastoma, soft tissue and bone
sarcoma, breast, ovarian, thyroid,
bronchiogenic, gastric and transitional
cell bladder carcinomas, HL, NHL




























MMAE is derived from peptides
found in Dolabella auricularia
MMAE enters cells expressing CD30,
potentiating microtubule inhibition in
addition to the antineoplastic effects of
brentuximab
HL after failure of ASCT or after failure
of two prior multiagent
chemotherapeutic regimens in those





DM1 is derived from maytansine,
which can be extracted from plants
of the genus Maytenus
DM1 enters cells expressing HER2/neu
receptor, potentiating microtubule
inhibition in addition to the
antineoplastic effects of trastuzumab


























Composed of diphtheria toxin fragments
linked to IL-2 sequences, interacts with
IL-2 cell surface receptors before
inhibiting protein synthesis
Persistent or recurrent CTCL in patients








Depletes asparagine, an amino acid
required by some leukemias
Component of a multiagent induction
regimen for ALL






Stabilizes formed microtubules Metastatic or locally advanced breast
carcinoma after failure of an





Unresolved, but does induce DNA strand
breaks
Squamous cell carcinomas, NHL,






Topo II inhibitor Testicular cancers, SCLC
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Table 1 continued
















Inhibits the growth phase of
microtubules without affecting the
shortening phase, sequesters tubulin
into nonproductive aggregates
Metastatic breast carcinoma that has
received at least two prior
chemotherapy regimens for late-stage








Inhibits mTOR by binding FKBP-12 Postmenopausal women with advanced
hormone receptor? and ER- breast
carcinoma, PNET, RCC, renal
















various species of the genus
Streptomyces
Binds DNA at the transcription initiation
complex and prevents elongation of












Stabilizes formed microtubules Ovarian carcinoma, breast carcinoma,
NSCLC, AIDS-related Kaposi’s
sarcoma
Abraxane Protein bound, conjugated to albumin Metastatic breast carcinoma, locally





Stabilizes formed microtubules NSCLC, breast carcinoma, prostate
adenocarcinoma, gastric












Inhibits tubule polymerization Acute leukemias, HL, NHL,
neuroblastoma, Wilms tumor,
rhabdomyosarcoma





Inhibits tubule polymerization Testicular cancers, HL, NHL, mycosis
fungoides, Kaposi’s sarcoma,
histiocytic lymphoma, Letterer-Siwe






Inhibits tubulin polymerization NSCLC
Underline indicates different formulations of the agent. Bold indicates that the compound is a synthetic or semisynthetic derivative of the original
natural product
AIDS acquired human immunodeficiency syndrome, ALL acute lymphoid leukemia, AML acute myeloid leukemia, ASCT autologous stem cell
transplant, CD cluster of differentiation, DM1 mertansine, CML chronic myeloid leukemia, CTCL cutaneous T-cell lymphoma, ER estrogen
receptor, FKBP12 12 kDa FK506 binding protein, HIV human immunodeficiency virus, HL Hodgkin’s lymphoma, IL-2 interleukin-2, MMAE
monomethyl auristatin E, mTOR mechanistic target of rapamycin, NHL non-Hodgkin’s lymphoma, NSCLC non-small-cell lung carcinoma,
PNET neuroendocrine tumors of pancreatic origin, RCC renal cell carcinoma, sALCL systemic anaplastic large-cell lymphoma, SEGA
subependymal giant-cell astrocytoma, SCLC small-cell lung carcinoma, Topo DNA topoisomerase, TKI tyrosine kinase inhibitor
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remains protein bound in circulation [3, 17]. The majority
of the agent is eliminated through bile emulsification and
fecal excretion. Eribulin is manufactured at 0.5 mg/mL
concentrations, and no routine premedication is needed.
One of the most common dosing schedules is 1.4 mg/m2
over 2–5 min on days 1 and 8 of a 21-day cycle, either
undiluted or diluted in 100 mL of 0.9 % normal saline [17].
Although this schedule is typically well tolerated, eribulin
is known to potentiate notable neutropenia ([grade 3 tox-
icity is *57 %), elevate transaminases, and induce
peripheral neuropathy (*8 % for grade 3 neuropathy and
0.4 % for grade 4 neuropathy).
Fig. 1 Molecular diversity of antineoplastic agents derived from natural products. AMU atomic mass unit, DM1 mertansine, MW molecular
weight, SMCC succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate
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Owing to the unique mechanisms by which eribulin
inhibits microtubule dynamics, the agent is FDA approved
for metastatic breast carcinoma refractory or relapsed on at
least two prior treatment protocols for late-stage disease,
including both anthracycline- and taxane-based
chemotherapies [18]. This approval stems in large part
from a phase III open-label study (n = 762) in which
eribulin improved overall survival [median of 13.1 months,
95 % confidence interval (CI) 11.8–14.3] in comparison to
treatments of the physicians’ choice (median of
10.6 months, 9.3–12.5; hazard ratio = 0.81, 95 % CI
0.66–0.99; p = 0.041) [19]. Peripheral neuropathy was the
most common adverse event leading to discontinuation
from eribulin, occurring in 24 (5 %) of 503 patients. In
addition, eribulin has also been investigated for use in a
variety of other solid tumors, including non-small-cell lung
carcinoma, head and neck carcinoma, pancreatic adeno-
carcinoma, prostate adenocarcinoma, and various sarco-
mas. Published data indicate that non-small-cell lung
carcinoma patients receive some benefit from eribulin, but
the agent does not appear to be effective in the treatment of
head and neck or pancreatic malignancies [20]. In addition,
eribulin appears to demonstrate activity against metastatic
castration-resistant prostate adenocarcinoma and advanced
soft-tissue sarcoma with a relatively favorable toxicity
profile being observed [21, 22].
3 Microtuble-Stabilizing Epothilones
Epothilones are 16-member macrolide microtubule-stabi-
lizing agents initially isolated in 1987 from the So ce90
strain of the myxobacterium Sorangium cellulosum [23,
24]. Originally investigated for their antimycotic activity,
samples of epothilones A and B sent to the National Cancer
Institute in 1994 demonstrated potent antineoplastic
activity in multiple cancer cell lines that was comparable
and sometimes superior to paclitaxel. However, a critical
difference between epothilones and other bulky natural
products or derivatives is that overexpression of ATP-
binding cassette (ABC) transporters does not significantly
alter the cytotoxicity of epothilones, as these congeners
have minimal substrate affinity for these proteins [25].
Epothilones A and B have marked anti-proliferative
activity in neoplastic cells with elevated levels of perme-
ability glycoprotein (P-gp) [26, 27], and tumor samples
obtained from patients that respond to ixabepilone have
shown significantly elevated levels of ABC transporters
P-gp and multidrug resistance-associated protein 1 [27]. It
should be noted that multidrug-resistance protein 7 is
capable of effluxing a variety of antineoplastic agents,
including epothilone B [28]. Although drug resistance to
taxanes is often associated with b-III subunit
overexpression, epothilones appear to be equally as potent
against cells demonstrating this phenotype [29, 30].
Whereas paclitaxel is less effective in suppressing the
growth rate and catastrophe frequency of purified a/bIII
tubulin, ixabepilone markedly suppresses the dynamic
instability of a/bIII dimers [31]. Further, ixabepilone has
exhibited substantially higher activity than either taxanes
or vinca alkaloids against neoplastic cells in vitro and
in vivo in which taxane resistance is associated with bIII
overexpression [32–34]. In regards to its structure-activity
relationship with tubulin, epothilones appear to bind the
taxane pocket of b-tubulin and promote structuring of the
M-loop into a short helix, as demonstrated by epothilone A
[35]. Consequently, the M-loop establishes lateral tubulin
contacts in microtubules, thereby potentiating microtubule
assembly and stability.
Modifications to the macrolide ring have been shown to
alter both the antineoplastic activity and pharmacologic
properties of epothilones. Second- and third-generation
congeners have been synthesized that possess higher
potency and enhanced water solubility compared with the
original natural products [32, 33]. Ixabepilone, a second-
generation semisynthetic analog of epothilone B has
nitrogen substituted at position 16 of the macrolide ring
instead of oxygen, making it a lactam [34] (Fig. 1). This
substitution increases water solubility and plasma stability
in comparison to epothilones B and D, but also reduces
cytotoxicity by one-fold [36]. In addition to ixabepilone, a
second semisynthetic derivative of epothilone B, BMS-
310705, a congener synthesized by the substitution of a
hydroxyl group with an amino group at C-21 of the
methylthiazole side chain, is 10-fold more water soluble
than epothilone B and is more cytotoxic than epothilone D
in multiple human neoplastic cell lines [37, 38]. Several
other recent novel epothilone derivatives have gained
notable preclinical and clinical interest. 20-Desmethyl-20
methylsulfanyl epothilone B (ABJ-879) is a second-gen-
eration derivative that exhibits more cytotoxicity than
epothilone B [39]. Sagopilone (ZK-EPO) is the first fully
synthetic, third-generation epothilone B derivative that
exhibits greater potency in vitro relative to the other epo-
thilones, retains activity in multidrug-resistant malignant
cells not observed in other congeners, and even crosses the
blood–brain barrier, indicating the potential for penetration
into the central nervous system [40]. The preclinical data
have been so compelling that sagopilone has been inves-
tigated at the clinical level against advanced solid tumors
and melanoma, with the agent demonstrating favorable
pharmacokinetic data, a feasible toxicity profile, and anti-
tumor activity against melanoma not elicted by other
congeners [41, 42]. Finally, a second-generation epothilone
D analog, KOS-1584, exhibits 3- to 12-fold increased
potency compared with epothilones B and D, enhanced
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neoplastic tissue penetration, and reduced central nervous
system toxicity [43].
Despite the isolation and characterization of epothilones
A–F, the only agent of this class to reach FDA approval is
ixabepilone. Although ixabepilone has better aqueous sol-
ubility than paclitaxel, Kolliphor EL is still typically used
as an excipient, and is contraindicated in patients who are
hypersensitive to the vehicle [44, 45]. Most clinical
investigations of ixabepilone have used a dosing schedule
of 32–50 mg/m2 infused over 1 or 3 h on day 1 of a 21-day
cycle. Nevertheless, a 3-h infusion time is recommended,
as more prominent neurotoxicity is often observed with
shorter infusion times, and the FDA-approved dose and
schedule is 40 mg/m2 intravenously (i.v.) over 3 h q3w
[46]. Multiple phase I/II trials have revealed that ixabepi-
lone exposure is not significantly affected by patient
characteristics (age, sex, renal function, body weight, body
surface area, race) [44, 47]. As with many mitotic inhibi-
tors, the most common grade 3 or 4 toxicity associated with
standard single-agent dosing schedules is neutropenia
(grade 3 neutropenia is observed in the range of 10–33 %,
while grade 4 neutropenia is observed in 7–32 % of
patients, the wide range likely being a reflection of the
number and type of prior therapies [46, 48–50].
Similar to eribulin, ixabepilone is currently indicated in
metastatic or locally advanced breast carcinoma that is
refractory or has relapsed on an anthracycline and a taxane,
and is typically administered in combination with capeci-
tabine [48, 50]. Interestingly, ixabepilone has shown
notable efficacy against triple-negative breast carcinoma
(TNBC), producing a pathologic complete response rate of
26 % in TNBC patients in comparison to 15 % in the non-
triple-negative population [51]. Concomitant administra-
tion of ixabepilone and capecitabine has resulted in higher
overall response rates than monotherapy, and a phase III
trial of ixabepilone plus capecitabine produced a median
progression-free survival significantly longer for TNBC
patients treated with ixabepilone plus capecitabine
(4.2 months) in comparison to treatment with capecitabine
alone (1.7 months) [51]. In addition to breast carcinoma,
ixabepilone has been investigated against non-Hodgkin’s
lymphoma and pancreatic adenocarcinoma, both as a stand-
alone agent and in concomitant chemotherapy [52–54].
4 Mechanistic Target of Rapamycin Inhibitors
Although medicinal chemists have made progress in per-
turbing the PI3K/AKT/mTOR (phosphatidylinositol-4,5-
bisphosphate 3-kinase/protein kinase B/mechanistic target
of rapamycin) pathway through the development of syn-
thetic compounds, the only mTOR inhibitors currently
FDA approved for chemotherapeutic intervention are
analogs of the macrolide rapamycin, a natural product
initially isolated from Streptomyces hygroscopicus in 1975
within the soils of Easter Island (also referred to as Rapa
Nui, giving rise to the name of the agent) [55–57].
Although currently used as an immunosuppressive agent,
rapamycin has also demonstrated marked cytostatic activ-
ity against several cancer types [58]. Its unique pharma-
cokinetic profile has prevented rapamycin from being
further developed as an antineoplastic agent, but its potent
mechanisms of action have inspired the development of
temsirolimus, a novel soluble rapamycin derivative that has
a favorable toxicity profile in mammalian models, thereby
potentiating the use of mTOR inhibitors in chemotherapy.
As of now, only temsirolimus and the later developed
analog everolimus have received FDA approval as anti-
neoplastic agents.
Rapamycin is a complex 21-member macrolide lactone
that contains a pipecolate moiety in the upper left region of
the molecule. The agent inhibits mTOR primarily by
crosslinking FKBP-12 (12 kDa FK506 binding protein) via
its methoxy functional group [59, 60]. The high affinity of
rapamycin to FKBP-12 is mediated in part by its pipecolate
region, which hydrogen bonds at two different hydrophobic
binding pockets, as revealed by X-ray crystallography [61–
63]. Once bound, the rapamycin/FKBP-12 complex blocks
the binding of the accessory protein RAPTOR (regulatory-
associated protein of mTOR) to mTOR, necessary for
downstream phosphorylation of S6K1 and 4EBP1. Con-
sequently, S6K1 dephosphorylates, which reduces protein
synthesis and decreases cell motility and size [64–66]. In
addition, rapamycin induces dephosphorylation of 4EBP1.
Such activity potentiates increases in p27, and decreases in
cyclin D1 expression, invoking late blockage of G1/S
during the cell cycle [66]. Although it is clear that rapa-
mycin induces apoptosis in neoplastic cells, the molecular
mechanism of apoptosis has not yet been fully resolved.
Temsirolimus has been an important addition to
chemotherapeutic protocols indicated for renal cell carci-
noma (RCC) owing to the importance of mTOR in car-
cinogenesis; in RCC tumors, activated mTOR further
exacerbates accumulation of HIF-1a (hypoxia-inducible
factor 1-a) by increasing synthesis of this transcription
factor and its angiogenic target gene products [67]. As
such, rapamycin and its analogs have demonstrated
notable antiangiogenic activity [68], indicating the poten-
tial of combining these congeners with agents that elicit
similar effects on neoplastic vasculature, including beva-
cizumab, sorafenib, and sunitinib [69, 70]. In addition to its
utility in RCC therapy, temsirolimus is being clinically
evaluated against other carcinomas known to have elevated
mTOR activity, including malignancies of the breast and
lung [71, 72]. Everolimus (Fig. 1) is an orally (p.o.)
administered 40-O-(2-hydroxyethyl) derivative of
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rapamycin that is currently indicated for postmenopausal
women with advanced hormone receptor positive and
estrogen receptor negative breast carcinoma, as well as
neuroendocrine tumors of pancreatic origin, RCC, renal
angiomyolipoma, and both pediatric and adult
subependymal giant cell astrocytoma [18]. The agent has
also been clinically evaluated against gastric adenocarci-
noma, hepatocellular carcinoma, and in multiple types of
lymphoma [73–75].
5 Protein Synthesis Inhibitor Omacetaxine
Mepesuccinate
Omacetaxine mepesuccinate (homoharringtonine) is a
natural ester of the alkaloid cephalotaxine, a compound
initially isolated and characterized in 1969 from Cepha-
lotaxus harringtonia (Japanese plum yew) [76] (Fig. 1).
Although cephalotaxine itself does not exhibit antineo-
plastic activity, fractionations of extracts obtained from
several variants of C. harringtonia produced a series of
cephalotaxine esters that demonstrated antineoplastic
activity. One of these compounds, homoharringtonine
(later renamed omacetaxine mepesuccinate), was shown to
influence the progression of acute myeloid leukemia
(AML) and chronic myeloid leukemia (CML) in China
during the 1970s, with later studies in the United States
confirming these findings [77, 78]. However, the clinical
development of omacetaxine mepesuccinate was halted
after the development of imatinib, which has since shown
remarkable activity in patients with Philadelphia chromo-
some positive CML and acute lymphoid leukemia (ALL).
Nevertheless, reemergence in the investigation of omac-
etaxine mepesuccinate quickly resumed once it was real-
ized that a subset of indicated leukemias are either
refractory or develop resistance to imatinib or related tyr-
osine kinase inhibitors (TKIs), particularly T315I subtypes.
Omacetaxine mepesuccinate elicits its antineoplastic
effects through inhibition of protein synthesis. Specifically,
the agent prevents aminoacyl-tRNA from binding the
ribosomal acceptor site, thereby preventing peptide bond
formation at the early stage of protein elongation [79]. In
addition, omacetaxine mepesuccinate inhibits the elonga-
tion phase of translation by preventing substrate binding to
the acceptor site on the 60s ribosome subunit, leading to
the blockade of aminoacyl-tRNA binding and peptide bond
formation [77, 80]. Further, it has been demonstrated that
the agent blocks protein synthesis by competing with the
amino acid side chains of incoming aminoacyl-tRNAs for
binding at the A-site of formed ribosomes [81]. Interest-
ingly, omacetaxine mepesuccinate has shown notable ac-
tivity against leukemic stem cells (LSCs) of CML origin
with the agent having a similar inhibitory effect on BCR-
ABL T315I-expressing LSCs in comparison to non-mutant
BCR-ABL-expressing LSCs [82], indicating that the agent
may be able to markedly inhibit clonal expansion in select
CML patients.
Unlike most antineoplastic agents, omacetaxine mepe-
succinate is administered subcutaneously (s.c.). with the
standard regimen being 1.25 mg/m2 s.c. b.i.d., days 1–14
every 28 days, with a maintenance treatment of 1.25 mg/m2
s.c. b.i.d. for 7 days every 28 days [79]. Omacetaxine
mepesuccinate disappears rapidly from plasma after ces-
sation of infusion, with an observed a-t1/2 of 5 h, a b-t1/2 of
9.3 h, and a mean steady-state terminal t1/2 of 7 h with
biexponential decay observed. The agent undergoes a rapid
metabolism with urinary excretion representing about
12–15 % of the administered dose. In addition, omac-
etaxine mepessucinate has a favorable toxicity profile with
effects on liver and cardiovascular function being the most
prominent [79–81, 83]. Owing to its efficacy in TKI-re-
sistant cells, omacetaxine mepesuccinate is FDA approved
for both chronic- and blast-phase CML [18], and clinical
trials are currently ongoing to determine optimal agents to
use in combination with the protein synthesis inhibitor.
Interestingly, not as much interest has been paid towards
the potential of omacetaxine mepesuccinate in Philadelphia
chromosome-positive ALL that is unresponsive to TKI
therapy, and may be an avenue of future clinical interest.
6 Nucleic Acid-Directed Trabectedin
Trabectedin is a novel antineoplastic agent that was iso-
lated from the sea squirt Ecteinascidia turbinate in 1984
[84, 85], and has a relatively complex structure; three
tetrahydroisoquinoline moieties, eight rings including one
10-membered heterocyclic ring containing a cysteine
residue, and seven chiral centers (Fig. 1). While the E.
turbinate extract that trabectedin is derived from was
shown to have antineoplastic activity as early as 1969 [84],
separation and characterization of the active molecules was
not feasible until the development of sufficiently sensitive
techniques. Further delaying its development was the fact
that yields from E. turbinate are extremely low; it takes
1000 kg of animals to isolate 1 g of trabectedin. It was not
until the development of synthetic methods of preparation
that actual clinical investigation was feasible. The current
supply of trabectedin is based on a semisynthetic process
starting from Safracin B, an antibiotic obtained by fer-
mentation of the bacterium Pseudomonas fluorescens [85].
Trabectedin is extremely potent, requiring only pico-
molar to low nanomolar concentrations to initiate cell death
in various cancer types in vitro [86–88]. This notable cy-
totoxicity is attributed to at least two separate actions;
DNA alkylation and inhibition of transcription. The agent
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binds the minor groove of DNA, showing a preference for
GG- and GC-rich regions, and then alkylates the exocyclic
N-2 on guanine [89, 90]. This alkylation step is dependent
on the dehydration of the carbinolamine (also referred to as
hemiaminal) group found on trabectedin, as this potentiates
the formation of an electrophilic iminium intermediate that
attracts nucleophilic DNA bases. Two subunits of tra-
bectedin form the primary contacts with DNA, while
another subunit protrudes out of the minor groove [91]. It is
this subunit that has been associated with the inhibition of
transcription, as interaction between the subunit and tran-
scription factors has been observed. Alkylation of DNA
produces the standard monoalkylating single-strand breaks
that proceed to double-strand breaks when the adduct is
recognized by the transcription-coupled nucleotide exci-
sion repair (TC-NER) complex [92, 93]. These in vitro
observations suggest that patients with BRCA mutations
may receive benefit from trabectedin, as BRCA1 locates
DNA damage and attracts the TC-NER complex to repair
DNA breaks, while BRCA2 mediates homologous recom-
bination by loading other proteins to the double-strand
break sites and stalled DNA replication forks [94, 95]. This
postulation has been confirmed in select patients with
ovarian carcinoma [93], making trabectedin particularly
attractive for certain subtypes of breast, lung, and ovarian
carcinoma with BRCA mutations.
Separating trabectedin from other alkylating agents is its
ability to inhibit the expression of potentially oncogenic
transcription factors, including those that code for onco-
gene products, c-myb, maf, and myc) and cell-cycle related
factors (E2F and SRF), and general transcription factors
(SCR, NF-Y, SXR, and Sp1) [96]. Its inhibition of P-gp
and heat shock protein 70 (Hsp70) expression through NF-
Y (as well as SXR, which is also responsible for P-gp
transcription) interaction are of particular intrigue [97, 98],
as both are integral to neoplastic drug resistance. Further,
trabectedin has profound activity on the tumor microenvi-
ronment, exerting effects on quiescent tumor-promoting
monocytes and macrophages that is atypical of a DNA-
directed alkylating agent [96].
Trabectedin has linear pharmacokinetics when admin-
istered as a 24-h i.v. infusion as is seen in the standard
dosing schedule of 1.5 mg/m2 over 24 h every 3 weeks
[99]. In addition, trabectedin is extensively bound to
human serum albumin, and the concentration of unbound
trabectedin in the plasma at clinically relevant trabectedin
plasma concentrations is in the picomolar range. Drug
metabolism presides mainly in the liver, with a large
number of metabolites being produced by cytochrome
P450 isozyme 3A4 and to a lesser extent by other cyto-
chrome P450 isozymes and phase II enzymes [99].
Trabectedin is approved in Europe (including Russia)
and South Korea for the treatment of advanced soft-tissue
sarcoma. This clinical indication has been validated by
multicenter phase II trials and a number of noncomparative
phase II trials [99, 100]. In addition, the European Com-
mission and the FDA have granted orphan drug status to
trabectedin for soft-tissue sarcomas and ovarian carcinoma.
The effects of trabectedin against ovarian carcinoma are
particularly intriguing; coadministration of trabectedin and
pegylated liposomal doxorubicin was associated with a
significantly longer (6 weeks; p = 0.019) median pro-
gression-free survival than pegylated liposomal doxoru-
bicin monotherapy in patients with recurrent ovarian
carcinoma after progression on platinum-based
chemotherapy [101]. In addition, concomitant administra-
tion of trabectedin and pegylated liposomal doxorubicin
was associated with a relative risk reduction (RRR) in
disease progression or death of 21 % (HR 0.79; 95 % CI
0.65, 0.96) in comparison to the doxorubicin monotherapy.
These findings are encouraging due to the fact that ovarian
carcinomas usually portend a poor prognosis (overall
5-year survival rate is 44 %, while stage IV invasive
ovarian carcinoma has a 5-year survival rate of 17 %)
[102]. The dearth of available treatment options for these
patients is apparent, warranting further investigation of
trabectedin and other novel therapeutic strategies. The
agent has also been investigated in breast carcinoma, lung
carcinoma, prostate adenocarcinoma [103–105], and vari-
ous pediatric sarcomas (Ewing’s sarcoma, and rhab-
domyosarcoma) [106].
7 Finding Novel Utility in Natural Products
through Improved Drug Delivery
The natural products discussed so far are potent antineo-
plastic agents, but are all inherently limited by their
untargeted cytotoxic mechanisms. Although malignant
cells are preferentially damaged as a result of increased
proliferation rates and increased uptake of the given agent,
normal tissue is also perturbed, preventing higher con-
centrations that could elicit more antitumor activity from
being administered. Further, there are natural products too
potent for clinical use because their activity is not specific
enough for neoplastic cells to garner any therapeutic ben-
efit. Finding a delivery system that discriminates between
neoplastic and normal cells, and then transports a cytotoxic
agent across the plasma membrane of aberrant cells to
induce apoptosis would therefore be an ideal situation. As
it turns out, the idea of preferentially delivering highly
cytotoxic natural products to neoplastic tissue has made
commendable progress in recent years owing to advances
in immunotherapy. By using epitopes highly expressed on
the cell surface of malignant cells, investigators have been
able to develop methods capable of transporting a drug
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payload to the intended target, substantially reducing the
toxicity of these agents had they not been conjugated to the
delivery protein. This targeted drug delivery can be
accomplished through two mechanisms; engineered cyto-
kine proteins and ADCs.
7.1 Engineered Cytokine Proteins
Cytokines are small proteins (*5–20 kDa) important for
various paracrine and autocrine signaling throughout the
body, but are most associated with their role in the immune
system. These proteins enable leukocytes to communicate
with one another to generate a coordinated, robust, but self-
limited response to a target antigen [107, 108]. Cytokines
themselves have been used for years in chemotherapy
because of their ability to directly stimulate immune
effector cells and stromal cells at the tumor site, and
enhance neoplastic cell recognition by cytotoxic effector
cells [108–110]. Interleukin-2 (IL-2) is particularly
appealing in hematological malignancies because the IL-2
receptor (IL-2R) is selectively expressed on activated T
lymphocytes, B cells, and natural killer cells [111]. In a
normal patient, IL-2R is expressed mostly at a low level in
less than 5 % of normal circulating peripheral blood
mononuclear cells [112]. However, many transformed
leukocytes have a high expression of high or intermediate
affinity IL-2R isoforms, particularly in cutaneous T-cell
lymphoma (CTCL) in which approximately 50 % of cases
express this phenotype as demonstrated by immunohisto-
chemical staining [112, 113]. Therefore, fusing a highly
cytotoxic agent to IL-2 may be an effective method by
which to target CTCL, while eliciting minimal toxicity to
non-hematological tissue.
7.2 Denileukin Diftitox
Denileukin diftitox is a fusion protein in which the receptor
binding domain of diphtheria toxin is exchanged for that of
IL-2 (Fig. 1) [114, 115]. Diphtheria toxin is produced
naturally in the pathogen Corynebacterium diphtheriae,
and is a single polypeptide chain of 535 amino acids
consisting of two subunits linked by disulfide bonds,
known as an A–B toxin [116, 117]. The less stable B unit
binds the cell surface of a target cell, enabling the more
stable A subunit to penetrate the plasma membrane. Once
internalized, the diphtheria toxin catalyzes the transfer of
NAD? to a diphthamide residue in eukaryotic elongation
factor-2 (eEF2) through ADP-ribosylation, resulting in its
deactivation (the same function of endogenous NAD?-
diphthamide ADP-ribosyltransferase) [118]. In essence,
this action halts translation, as eEF2 facilitates the move-
ment of the peptidyl tRNA-mRNA complex from the A site
of the ribosome to the P site during protein synthesis;
thereby potently inhibiting the production of new proteins.
Consequently, diphtheria toxin is extraordinarily potent
with the average human lethal dose being *0.1 lg/kg
[118].
Through human innovation, one of the deadliest toxins
in nature can be harnessed for cancer therapy once it is
given the appropriate delivery system. Denileukin diftitox
contains the full-length sequence of IL-2, as well as protein
fragments of diphtheria toxin; 97 amino acids from the
native part of the toxin containing the disulfide bond are
removed to increase the half-life and affinity of the com-
pound to its target receptor [119, 120]. After diphtheria
toxin and IL-2 are fused together, the agent seeks out
CD25-bearing cells, as CD25 represents the high-affinity
a-subunit of the IL-2 receptor. CTCL cells internalize the
agent via receptor-mediated endocytosis after it binds
IL-2R, and is subsequently acidified inside the vesicle. This
process releases diphtheria toxin fragment A into the
cytoplasm, enabling the internalized fragment A to cat-
alyze the transfer of ADP to eEF2. Premature ADP-ribo-
sylation of eEF-2 inhibits further protein synthesis,
ultimately potentiating apoptosis [121, 122].
There are limitations to the delivery mechanism by
which denileukin diftitox acts. In addition to the expected
immunosuppression and potential for bacterial infections,
the agent is known to cause acute hypersensitivity-type
reactions, asthenia, and nausea/vomiting [123]. Further, the
use of IL-2 as a method to selectively transfer diphtheria
toxin into CTCL cells is inherently limited. IL-2Rs are
classified into three subtypes based on their affinity for
IL-2. Each subtype is composed of a combination of
subunits: a (CD25 and p 55), b (CD122 and p 75), and
c (CD132 and p 64). Intermediate and high-affinity
receptors are composed of IL-2R-b/c (CD122 and CD132)
and IL-2R-a/b/c (CD25, CD122, and CD133) subunits,
respectively, and both perpetuate internalization and signal
transduction. By contrast, low-affinity receptors consist of
the IL-2R-a/c (CD25 and CD132) subunits that bind IL-2,
but do not cause internalization or activation [112, 124,
125]. Therefore, the presence of the b and c (CD122 and
CD132) subunits is essential for sensitivity and internal-
ization of the fusion toxin. If CTCL cells are lacking
appropriate receptors, denileukin diftitox will be ineffec-
tive, paving the way for potential drug resistance.
Nevertheless, denileukin diftitox has elicited notable re-
sponses in patients, and the agent is currently FDA
approved for persistent or recurrent CTCL in patients
expressing the critical CD25 component of IL-2R [18].
Because the expression of IL-2R is vital for the T-cell
targeting of denileukin diftitox, strategies to upregulate
IL-2R expression are of particular clinical interest. Reti-
noids are a particularly attractive concomitant agent, as they
have immunomodulatory function and have been shown to
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increase IL-2R expression on T-cells [126, 127]. It has been
demonstrated that both bexarotene and alitretinoin are
modulators of high affinity IL-2R expression, as the agents
increase the expression of CD25 and CD75 in CTCL cells.
These CTCL cells can be subsequently exposed to deni-
leukin diftitox, resulting in a 50–70 % decrease in protein
synthesis [126]. This is particularly exciting because bex-
arotene is already standard therapy for patients with early-
and advanced-stage CTCL. The concomitant use of deni-
leukin diftitox and retinoids is currently being clinically
investigated [128, 129], and may potentiate a novel avenue
of chemotherapy for CTCL patients.
7.3 Antibody-Drug Conjugates
Immunoconjugates are a relatively novel class of
chemotherapeutic agents that are gaining increasing inter-
est because of their efficacy and reduced side effects in
comparison to some traditional cytotoxic agents. If tradi-
tional chemotherapy is equivalated to indiscriminate
bombing, immunoconjugates are roughly analogous to
modern day missile guidance systems. These agents consist
of three main components; the monoclonal antibody (mAb;
guidance system), the degradable linker (delivery mecha-
nism), and the cytotoxic agent (warhead) that can either be
a toxin or a radioisotope. While not completely specific to
neoplastic tissue, immunoconjugates target a given epitope
based on the mAb that is chosen, enabling the use of
cytotoxic agents that would likely elicit too broad of a
toxicity profile in a typical patient. Although the scope of
this review limits commentary to ADCs, radioim-
munotherapy has shown efficacy in a variety of cancers,
and the reader would benefit from the following reviews
[130–132].
7.4 Brentuximab Vedotin
Brentuximab vedotin is a conjugate of a humanized CD30-
targeting mAB and monomethyl auristatin E (MMAE)
linked via a cathepsin cleavable linker (valine-citrulline)
and a para-aminobenzylcarbamate (PABC) spacer (the
name vedotin refers to MMAE plus its linking structure to
the mAB) [133–136]. MMAE is a potent mitotic inhibitor
derived from the naturally occurring dolastatin 10 that was
isolated from Dolabella auricularia (wedge sea hare) in
1987 [137]. Several related molecules have since been
produced through total syntheses, establishing the drug
class auristatin [138]. As with vinca alkaloids, the auris-
tatins exert antineoplastic activity by inhibiting tubulin
polymerization. However. these agents are much more
toxic (MMAE is 200 times more potent than vinblastine)
[139], substantially limiting their clinical utility. MMAE
was subsequently developed with a built-in functionality
for stable linker attachment, and still retains high potency
in addition to exhibiting water solubility and stability under
physiological conditions [133]. The ability to conjugate
MMAE to mABs and potentially other proteins has con-
siderably increased the utility of auristatins, enabling these
once intolerable agents to be directed towards the intended
target, thereby dramatically reducing unintended toxicity.
CD30 is an ideal target for ADCs because the antigen is
a tumor necrosis factor receptor that stimulates apoptosis,
and is highly expressed in Hodgkin’s lymphoma, systemic
anaplastic large cell lymphoma, CTCL, and other selected
lymphoid tumors [140, 141], as well as in some non-lym-
phoid malignancies including germ cell tumors [141, 142].
Further, cross-reactivity of CD30 on normal tissues is very
low, with some expression on activated T and B lympho-
cytes; this expression is not observed on resting T and B
lymphocytes [141]. In addition to the CD30-targeting
mAB, brentuximab vedotin employs a protease-cleavable
linker because protease activity is abundant in lysosomes,
where ADCs are often directed [133]. In addition, protease
activity is significantly reduced outside of cells owing to
secreted protease inhibitors [141]. MMAE is attached to
suitable degradable peptides through the built-in N-termi-
nal amine functionality via the self-immolative spacer
(PABC). The spacer is required so that the cleavable
peptide is situated away from MMAE to allow facile pro-
teolysis. Val-Cit (the clevable peptide) is stable in plasma,
but is rapidly hydrolyzed via proteolysis by cathepsin in
lysosomes [143]. Upon peptide cleavage, the PABC group
rapidly fragments, releasing the highly cytotoxic MMAE
into the cytoplasm.
Brentuximab vedotin is currently indicated for Hodg-
kin’s lymphoma after failure of an autologous stem cell
transplant or after failure of two prior multiagent
chemotherapeutic regimens in those who are not suit-
able for autologous stem cell transplantation, as well as
systemic anaplastic large cell lymphoma. Due to the
prevalence of CD30 in various malignancies, brentuximab
vedotin is also being investigated in patients with CTCL,
other CD30-positive hematological malignancies, and
CD30-positive germ cell tumors [144].
7.5 Trastuzumab Emtansine
Trastuzumab emtansine is an ADC consisting of the
humanized HER2/Neu-targeting mAB trastuzumab linked
to mertansine (DM1) via SMCC (succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate), a heterobi-
functional crosslinker (Fig. 1) [145, 146]. While trastuzu-
mab is already effective against HER2-positive breast
carcinomas, esophageal carcinomas, and gastric adenocar-
cinomas [147, 148], conjugating the mAB with the highly
cytotoxic DM1 is an effective method to generate activity
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in refractory or relapsed tumors [149–151]. DM1 refers to
mertansine, a derivative of maytansine that has been
chemically modified to have a terminal thiol for conjuga-
tion. Maytansine is a macrolide of the ansamycin type
(contains an aromatic moiety bridged by an aliphatic chain)
that was originally isolated in 1972 from the flowering
plant Maytenus ovatus [152]. Similar to MMAE, may-
tansine is a highly potent microtubule inhibitor that by
itself lacks the tumor specificity required to elicit thera-
peutic benefit [153, 154]. It was not until the development
of ADCs that the extremely cytotoxic potential of may-
tansine could be harnessed in the form of conjugate-com-
patible DM1.
Trastuzumab is a logical choice for ADC enhancement
because its target HER2/Neu is preferentially overex-
pressed in certain subtypes of breast carcinoma, esophageal
carcinoma, and gastric adenocarcinoma. In particular, gain-
and loss-of-function experiments, as well as immunohis-
tochemistry analyses have indicated HER2 amplification as
a driving event in the onset and progression of as much as
25–30 % of breast carcinomas [155, 156]. Further, this
subtype of breast carcinoma is often very aggressive and
resistant to traditional cytotoxic chemotherapy [157, 158].
Due to its apparent oncogene addiction, targeting HER2
positive breast carcinomas through this vital receptor has
become an attractive approach for therapeutic intervention.
Each molecule of trastuzumab emtansine consists of a
single trastuzumab mAB with several molecules of DM1
attached; trastuzumab may be conjugated with up to 8
DM1 molecules (three to four on average) [159, 160].
SMCC contains two reactive functional groups, a succin-
imide ester and a maleimide. The succinimide group of
SMCC reacts with the free amino group of a lysine residue
in the trastuzumab molecule, and the maleimide moiety of
SMCC links to the free sulfhydryl group of DM1, forming
a covalent bond between the mAB and DM1 [160].
After binding HER2, trastuzumab emtansine gains entry
to the cellular interior via receptor-mediated endocytosis
[161]. Since the non-reducible SMCC linker is stable in
circulation, as well as in the tumor microenvironment,
DM1 release occurs only as a result of proteolytic degra-
dation of the mAB part of trastuzumab emtansine in the
lysosome. Following release from the lysosome, DM1-
containing metabolites potently inhibit microtubule
assembly, causing cell-cycle arrest at the G2/M checkpoint,
eventually triggering apoptotic mechanisms [162, 163].
Importantly, linkage of DM1 to trastuzumab does not affect
the binding affinity of trastuzumab to HER2, nor does it
reduce the inherent antineoplastic effects of trastuzumab
[162, 164, 165]. Consequently, trastuzumab emtansine
benefits from the mechanisms of both trastuzumab and
DM1.
Trastuzumab emtansine is currently FDA approved for
HER2-positive breast carcinoma, HER2-positive meta-
static gastric adenocarcinomas, and gastroesophageal ade-
nocarcinoma with HER2 overexpression [18]. In the USA,
trastuzumab emtansine is typically reserved for the treat-
ment of HER2-positive metastatic breast carcinoma in
patients who have been treated previously with trastuzu-
mab and a taxane (paclitaxel or docetaxel), and who have
already been treated for metastatic breast cancer or
developed tumor recurrence within 6 months of adjuvant
therapy [166]. This is due in part to the expense of tras-
tuzumab emtansine treatments, as protocols can cost
patients US $9800 a month, or US $94,000 for a typical
course of treatment. Since trastuzumab and pertuzumab
(another HER2/Neu-targeting mAB) bind different epi-
topes [167, 168], clinical investigation has also been
extended to concomitant chemotherapy consisting of both
trastuzumab emtansine and pertuzumab against unre-
sectable HER2-positive breast carcinoma that is locally
advanced or metastatic [169].
7.6 Calicheamicin Conjugated Monoclonal
Antibodies
The cytotoxic agents available for mAB conjugation are
not limited to highly potent microtubule inhibitors. Perhaps
the most notable example is calicheamicin conjugated
mABs. Calicheamicins are a class of enediyne nucleic
acid-directed agents that were initially characterized in
1989 from the fermentation broth of the bacterium
Micromonospora echinospora [170]. Since then,
calicheamicin c1 and the related enediyne esperamicin
have become known as two of the most potent antineo-
plastic agents in existence [171]. As is the case with most
extremely cytotoxic agents, their utility would come not as
stand-alone agents, but rather as components of epitope-
targeting ADCs. The initial attempt to harness the potency
of calicheamicins was with gemtuzumab ozogamicin, a
humanized CD33-targeting mAB conjugated to a carbo-
hydrate conjugate of N-acetyl-c calicheamicin dimethyl
hydrazide via a bifunctional AcBut linker (4-(40-
acetylphenoxy)butanoic acid) [172, 173]. Gemtuzumab
ozogamicin was the first FDA-approved ADC, being
approved for the treatment of AML in 2000. Unfortunately,
this initial attempt also elicited marked unintended toxicity
(most notably the potentiation of sinusoidal obstruction
syndrome) [174–176], and was withdrawn from the market
in 2010 after a randomized, phase III comparative con-
trolled trial demonstrated that the agent increased patient
death and added no benefit over conventional cancer
therapies [177]. Nevertheless, an additional calicheamicin
conjugated mAb has since been developed (inotuzumab
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ozogamicin), and calicheamicin congeners are still being
investigated for their antineoplastic potential.
The extreme potency of calicheamicins can be traced
back to their unique mechanism of action. All calicheam-
icins appear to interact with cellular DNA and initiate
double-strand cleavage by carbon-centered diradical
hydrogen abstraction processes [178, 179]. Calicheamicins
bind DNA in the minor groove, wherein they undergo a
reaction analogous to a Bergman cyclization to generate a
diradical species. This diradical, 1,4-didehydrobenzene,
then abstracts hydrogen atoms from the deoxyribose
backbone of DNA, ultimately resulting in irreversible
strand scission [180]. The affinity of calicheamicin c1 for
the minor groove of DNA is due its aryltetrasaccharide
domain [181, 182]. Specifically, calicheamicin c1 binds the
DNA minor groove with its aryltetrasaccharide domain in
an extended conformation spanning TCCT/AGGA seg-
ments of DNA. Calicheamicin c1 then inserts itself in an
edgewise manner deep into the minor groove with the
molecule wedged between the walls of the groove [182]. A
range of intermolecular hydrophobic and hydrogen-bond-
ing interactions are also observed, accounting for the
sequence-specific recognition in the complex.
In addition to gemtuzumab ozogamicin, another
calicheamicin-conjugated humanized mAB, inotuzumab
ozogamicin has reached phase III clinical trials. Rather
than targeting CD30, inotuzumab ozogamicin consists of a
humanized mAb that recognizes the CD22 antigen. Nev-
ertheless, this mAB is still conjugated to N-acetyl-c-
calicheamicin dimethyl hydrazide via the acid labile 4-(40-
acetylphenoxy)butanoic acid linker [183]. Since CD22 is a
B-lymphocyte-restricted phosphoglycoprotein [184], ino-
tuzumab ozogamicin has been clinically examined in
B-cell leukemias and lymphomas with reversible throm-
bocytopenia as the main toxicity observed. [185, 186]. It
should be noted that CD22 may be expressed in certain
lung carcinomas, but this is still inconclusive, as the data
have been conflicting [187, 188]. The ADC has shown
notable efficacy against pediatric and adult ALL resistant
to traditional cytotoxic chemotherapy [186, 189], and is
indicative of the potential ADCs have in previously unre-
sponsive cancers.
7.7 Exotoxin Conjugates
Antibody/toxin conjugates are not limited to small-mole-
cule cytotoxic agents. In a manner similar to denileukin
diftitox, mABs have now been successfully conjugated to
large protein bacterial exotoxins, thereby increasing the
diversity of available immunotoxins. The two most well-
known examples are moxetumomab pasudotox and SS1P.
Moxetumomab pasudotox is a recombinant immuno-
toxin composed of the Fv fragment of a fully human CD22-
targeting mAB fused to a 38-kDa fragment of Pseu-
domonas exotoxin A [190]. Moxetumomab pasudotox is
actually an improved, more active form of a predecessor
recombinant immunotoxin, BL22 (also called CAT-3888),
which produced complete remission in relapsed/refractory
hairy cell leukemia (HCL), but had a\20 % response rate
in chronic lymphoid leukemia (CLL) and ALL, which are
noted for containing much lower numbers of CD22 [191,
192]. Compared with BL22, moxetumomab pasudotox is
up to 50-fold more active against CLL and HCL [193].
Pseudomonas exotoxin is a highly cytotoxic product of
the pathogenic bacterium Pseudomonas aeruginosa [194].
With a mechanism very similar to diphtheria toxin, the
exotoxin potently inhibits eEF2 through ADP-ribosylation,
thereby ceasing further elongation of polypeptides. Crys-
tallographic studies have demonstrated that Pseudomonas
exotoxin is made up of three major structural domains;
domain Ia is the cell binding domain, domain Ib contains
no known function, domain II contains a furin site neces-
sary to release domain III from the cell binding domain,
and domain III contains the ADP-ribosylating activity that
inactivates eEF2 [194].
In recombinant immunotoxins targeting CD22 (BL22
and moxetumomab pasudotox), domain Ia of PE is
removed and replaced by the Fv portion of a mAB reacting
with CD22 [190]. Because BL22 was limited by the lower
expression of CD22 in CLL and ALL, the mAB portion of
the agent was improved. By mutating three residues in the
heavy chain of the BL22 Fv (residues 100, 100a, and
100b), investigators were able to increase the affinity of the
mAB to HCL by about 15-fold and cytotoxicity toward
HCL and CLL cells by up to 50-fold [193]. This
improvement in binding affinity and increased cytotoxicity
did not interfere with pharmacokinetics or off-target toxi-
city, indicative of superior antineoplastic potential. Mox-
etumomab pasudotox has produced complete responses
against CD22 positive leukemias in the clinical setting,
demonstrating particular promise with relapsed and
refractory HCL [195]. Phase III evaluations are currently
underway to fully assess the efficacy of moxetumomab
pasudotox in comparison to more established therapeutic
approaches.
In addition to its potential with CD22-targeting mAB
Fvs, the pseudomonas exotoxin has also been fused with an
anti-mesothelin Fv to create SS1P. Mesothelin is a 40-kDa
cell surface glycoprotein present on some normal
mesothelial cells lining the pleura, peritoneum, and peri-
cardium [196, 197]. However, mesothelin is also highly
expressed in several malignancies, including epithelial
mesotheliomas (*100 % of cases), lung carcinomas
(*50 % of cases), ovarian carcinomas (*70 % of cases),
and pancreatic/biliary adenocarcinomas (*100 % of
cases) [198–201], thereby being an epitope of particular
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antineoplastic interest. SS1P acts by the same mechanism
as moxetumomab pasudotox and is very similar in struc-
ture, but is specific for mesothelin-positive cells. This
epitomizes the utility of immunoconjugates, as the same
highly toxic small molecule or protein can be directed
towards different targets once linked to an appropriate
effector. Demonstrating potent antitumor activity in pre-
clinical in vivo models [202–204], SS1P has since pro-
gressed towards clinical examination. Owing to its
response in mesothelioma patients during phase I trials
[205–207], SS1P has gained particular attention in the
treatment of this malignancy. Nevertheless, SS1P has also
been clinically investigated in other cancers with high
mesothelin expression, and the agent may gain traction as a
multipurpose immunotoxin.
8 Natural Products with Mechanisms Not
Currently Seen in the Clinical Setting
Although the diversity of natural products currently used in
the clinical setting is considerably immense, it is not
comprehensive. There are in fact many other potential
targets inherent to cancer pathology that could be exploited
through the implementation of novel natural products. One
target of considerable importance is the cytoskeleton. Not
only do many malignant cells have a perturbed cytoskele-
ton owing to the effects of dysplasia and subsequent ana-
plasia [208, 209], but the cytoskeleton has also been
indicated in oncogenic signaling and metastatic progres-
sion [210–212]. While microtubule-directed agents have
been a mainstay in traditional cytotoxic chemotherapy,
they are inherently limited to one component of the
cytoskeleton. The other potential targets, intermediate fil-
aments and microfilaments, have remained as elusive
clinical prospects.
Cytoskeletal filaments are indeed viable targets to
exploit in chemotherapy. Microfilaments are inherently
required for cell motility, cytokinesis, and many other
processes vital for malignant cell stability [213–216].
Intermediate filaments such as keratins are often overex-
pressed in carcinomas as a result of the aberrant effects of
associated oncogenes [217, 218], and vimentin has been
shown to be vital for cell survival in numerous experiments
[219–221]. Although there has yet to be a microfilament- or
intermediate filament-directed agent approved for clinical
use, nature offers potential solutions to these previously
elusive targets. Through the course of evolution, a con-
siderable assortment of small molecules has been devel-
oped by various organisms that perturb the dynamics of
actin polymerization or intermediate filament formation,
and have demonstrated profound preclinical antineoplastic
activity. A comprehensive review of cytoskeletal filament-
directed agents available for further preclinical investiga-
tion has already been compiled [222]. Therefore, the
potential of exploiting each currently untargeted compo-
nent of the cytoskeleton will be briefly highlighted by two
drug classes; cytochalasins and withanolides.
8.1 Cytochalasins
As indicated by both in vitro and in vivo investigation,
microfilaments are vital for the progression of many
malignancies, and are therefore a suitable target for
chemotherapy. One of the most studied drug classes of
microfilament-directed agents has been the cytochalasins,
which were initially characterized in 1967 as being bio-
logical metabolites of the molds Helminthosporium
dematiodeum (cytochalasins A and B) and Metarrhizium
anisopliae (cytochalasins C and D) [223]. It has since been
discovered that these mycotoxins potently inhibit actin
polymerization, affecting activities ranging from cell
motility and adhesion to cytokinesis. Since their initial
discovery, more than 60 different cytochalasins from sev-
eral species of fungi have been classified into various
subgroups based on the size of the macrocyclic ring and the
substituent of the perhydroisoindolyl-1-one residue at the
C-3 position [224]. While all cytochalasins demonstrate the
propensity to bind filamentous (F)-actin and block poly-
merization, only cytochalasins B and D have been exten-
sively studied for their chemotherapeutic potential. Both
congeners bind the fast growing barbed end of microfila-
ments, essentially fulfilling the role of capping proteins that
prevent further actin polymerization once the filament has
grown to a sufficient length [222]. However, cytochalasin
D is more potent than cytochalasin B, reflected by
cytochalasin B being 20-fold less toxic in mice than
cytochalasin D [225], a pharmacological property attrib-
uted to the affinity cytochalasin D also has for globular
(G)-actin.
Although only a handful of laboratories have investi-
gated the potential of cytochalasins as antineoplastic
agents, enough studies have been performed to establish
mechanisms by which these agents exert their antineo-
plastic effects (Fig. 2). In preclinical mammalian models of
malignancy, cytochalasins B and D exhibit marked anti-
tumor and antimetastatic activity in murine melanomas
(B16BL6 and B16F10), lung carcinomas (LA4, Lewis
Lung, and M109), leukemias (P388 and P388/ADR), and
M5076 sarcoma administered intraperitoneally, intra-
venously, or subcutaneously [226–239]. In addition, the
pharmacokinetics, tissue distribution, and potential toxici-
ties of cytochalasin B and liposome-encapsulated
cytochalasin B have been extensively characterized [228–
231]. The only major toxicity consistently elicited by
cytochalasin B is marked immunosuppression, which has
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been characterized in multiple murine models [230, 231].
Nevertheless, this in vivo toxicity can be markedly reduced
either through the administration of human recombinant
IL-2, or liposome encapsulation [228, 229, 231]. Further,
liposome encapsulated cytochalasin B shows equal, or even
superior antitumor activity in M109 lung carcinoma in vivo
when compared with the non-encapsulated compound
[228]. It has also been demonstrated by Huang et al. [232]
that a pegylated formulation of cytochalasin D is more
water soluble, accumulates in tumor tissue more efficiently,
and has a much longer t1/2 than natural cytochalasin D (4 h
vs. 10 min), while still retaining the antitumor activity of
the natural compound.
8.2 Withanolides
Along with microfilaments, intermediate filaments are the
other component of the cytoskeleton that has yet to be
exploited in the clinical setting. It has been repeatedly
demonstrated that a variety of malignancies have aberrant
or an elevated expression of intermediate filaments keratin
(type I or II), nestin (type VI), and vimentin (type III)
[233–242]. Although no potential antineoplastic agent has
been identified to specifically target aberrant keratin or
nestin levels in malignant cells, withanolides have shown
promise as a potent type III intermediate filament
inhibitor.
The most promising clinical prospect of this drug class
is withaferin A, a steroidal lactone that was initially iso-
lated from Withania somnifera (winter cherry) in 1965
[243], and was the first member of the withanolides to be
discovered. Withaferin A has been shown to potently
inhibit a variety of proteins, with the most notable target
being vimentin and other type III intermediate filaments
[244–248] (Fig. 3). In addition to its affinity for interme-
diate filaments, withaferin A has been shown repeatedly to
inhibit angiogenesis [247–251], with potent anti-angio-
genic activity being exerted at doses as low as 7 lg/kg/day
intraperitoneally in C57BL/6J mice [250].
Withaferin A also elicits antineoplastic activity in a
considerable variety of cancer cell lines by directly
inhibiting neoplastic growth, including carcinomas of the
breast, head and neck, ovaries, and thyroid, as well as
glioblastoma multiforme and melanoma [251–255]. Owing
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Cell Migraon
Inhibit cell migraon and the secreon of 
glucosaminidases used to degrade carbohydrates in 
the extracellular matrix, potenang marked an-
metastac acvity. 
Inhibit drug eﬄux by binding ATP-binding cassee 
proteins, enhancing the acvity of other 
anneoplasc agents.
Fig. 2 Antineoplastic mechanisms of microfilament-disrupting cytochalasins. MW molecular weight
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to its notable anti-angiogenic activity, withaferin A has
demonstrated significant synergistic effects with the mul-
tikinase inhibitor sorafenib [256], suggesting that with-
aferin A may be a viable supplement for renal cell
carcinomas, and other malignancies notably affected by the
inhibition of neoplastic angiogenesis. It should also be
noted that withaferin A, withalongolide A (a 19-hydroxy
derivative of withaferin A), and several other closely
related congeners may influence signaling regulated by the
PI3K/AKT/mTOR pathway. These congeners suppress
RET and Akt phosphorylation and protein expression, as
well as inhibit mTOR activity, the translational activity of
4EBP1, and protein synthesis mediated by p70S6 kinase
activation in neoplastic cells [patient-derived medullary
thyroid carcinoma cells, as well as human (U87 and U251)
and murine (GL26) glioblastoma cells] in vitro [257, 258].
These data indicate a potential synergistic relationship
between withanolides and mTOR inhibitors currently used
in the clinical setting, and warrant further preclinical
investigation.
9 Conclusion
Beginning with the VAMP (vincristine, amethopterin/
methotrexate, 6-mercaptopurine, and prednisone) protocol
that potentiated long-term survival in pediatric ALL for the
first time in medical history [259], natural products have a
long history as antineoplastic agents. They have repeatedly
added to the mechanisms of action available to practicing
clinicians, as well as inspire semi-synthetic derivations that
demonstrate improved clinical utility. Although sometimes
archaic by their less than ideal discrimination of neoplastic
over normal tissue, these agents are still highly imple-
mented in many forms of chemotherapy. In an age where
clinicians are becoming ever more sophisticated in their
ability to target solid tumors and disseminated cancers with
small-molecule inhibitors and the rapidly expanding field
of immunotherapy, we should not lose sight of the
importance of natural products for the treatment of cancer.
Epitomized by ADCs, natural products previously deemed
too potent to elicit therapeutic benefit can now be
Inhibits the formaon of all type 3 intermediate 
ﬁlaments. 
Reduces neoplasc angiogenesis by inducing 
endothelial cell death via vimenn modiﬁcaon at 
the conserved rod 2B domain, and through inhibion 
of VEGF.
Elicits anneoplasc eﬀects by downregulang 
chymotrypc acvity in the proteasome, 
consequently increasing the amount of 
ubiquinated proteins and pro-apoptoc 
proteins targeted by the proteasome. 
Withaferin A also downregulates important 
oncoproteins such as survivin. 
Has synergisc acvity with sorafenib, and 
potenally other VEGF small molecule inhibitors or 
VEGF-targeng mABs. 
Fig. 3 Antineoplastic mechanisms of intermediate filament-disrupting withaferin A. MW molecular weight, VEGF vascular endothelial growth
factor
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conjugated to an appropriate protein delivery system,
thereby delivering highly cytotoxic and specific treatments
to neoplastic tissue. This is an important lesson, as there are
currently many cytotoxic mechanisms of action employed
in nature that are not currently used in the clinical setting,
such as the microfilament-targeting cytochalasins, or the
intermediate filament-targeting withanolides.
While precision medicine has captivated the field of
oncology in recent years and is gaining an increasing
foothold in the clinic, we should also not discourage the
continual investigation of natural products as antineoplastic
agents. As demonstrated by current protocols, their unique
mechanisms can be coupled with synthetic inhibitors or
genetically modified proteins to create effective first-line
therapies. Further, some derivatives of natural products
such as the rapamycin analogs have the potential to be used
in select cancers that demonstrate specific aberrant signal-
ing cascades. Nature has already done the hard work
through years of evolutionary pressures. Now, modern
medicine can harness these complex, but often synthetically
reproducible molecules, to develop ever more comprehen-
sive and effective treatment modalities. As demonstrated by
the countless lives they have prolonged or even saved,
natural products have, are still, and will continue to function
as vital components of cancer chemotherapy.
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